Invivyd to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) announced its participation in two upcoming investor conferences in New York. The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 12:00 PM ET.
The presentations will be available via live webcasts on the company's investor website and archived for approximately 30 days. Management will also host investor meetings during both conferences.
Details
News Market Reaction – IVVD
On Aug 27, the day this news came out, IVVD closed 15.44% below the previous close. That session’s volume was 2.0x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences:
Cantor Global Healthcare Conference 2025
Fireside Chat Date: Wednesday, September 3, 2025
Fireside Chat Time: 2:10 PM ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date: Monday, September 8, 2025
Fireside Chat Time: 12:00 PM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 30 days following each event.
In addition to the fireside chats, the management team will host investor meetings at the conferences. Investors participating in the conferences who are interested in meeting with Invivyd management should contact their Cantor or H.C. Wainwright representative.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.